KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $21.4 million.

  • GoodRx Holdings' Depreciation & Amortization (CF) rose 2221.84% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 1369.7%. This contributed to the annual value of $69.5 million for FY2024, which is 3541.44% down from last year.
  • Per GoodRx Holdings' latest filing, its Depreciation & Amortization (CF) stood at $21.4 million for Q3 2025, which was up 2221.84% from $19.7 million recorded in Q2 2025.
  • GoodRx Holdings' Depreciation & Amortization (CF)'s 5-year high stood at $43.6 million during Q4 2023, with a 5-year trough of $5.4 million in Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $17.3 million, with a median of $15.9 million in 2024.
  • Per our database at Business Quant, GoodRx Holdings' Depreciation & Amortization (CF) soared by 18074.42% in 2023 and then crashed by 5620.99% in 2024.
  • Over the past 5 years, GoodRx Holdings' Depreciation & Amortization (CF) (Quarter) stood at $10.6 million in 2021, then surged by 45.88% to $15.5 million in 2022, then surged by 180.74% to $43.6 million in 2023, then crashed by 56.21% to $19.1 million in 2024, then rose by 12.23% to $21.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $21.4 million for Q3 2025, versus $19.7 million for Q2 2025 and $20.9 million for Q1 2025.